Press release
Helicobacter Pylori Infections Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, Involved by DelveInsight | Phathom Pharma, HK inno.N Corporation, Elpen Pharma, Deva Holding
"Helicobacter Pylori Infections Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Helicobacter Pylori Infections Market.
The Helicobacter Pylori Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Helicobacter Pylori Infections Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Helicobacter Pylori Infections treatment therapies with a considerable amount of success over the years.
*
Helicobacter Pylori Infections companies working in the treatment market are Servatus Biopharmaceuticals, TenNor Therapeutics (Suzhou) Limited, Phathom Pharmaceuticals, Inc., HK inno.N Corporation, Elpen Pharmaceutical Co. Inc., Deva Holding A.S., Lallemand Health Solutions, Takeda, Meridian Bioscience, Inc., Janssen Cilag Pharmaceutica S.A.C.I., Greece, RedHill Biopharma Limited, Il-Yang Pharm. Co., Ltd., Asan Medical Center, MerLion Pharmaceuticals GmbH, TenNor Therapeutics (Suzhou) Limited, and others, are developing therapies for the Helicobacter Pylori Infections treatment
*
Emerging Helicobacter Pylori Infections therapies in the different phases of clinical trials are- SVT1C4610, TNP-2198, Vonoprazan, Tegoprazan, Esomeprazole, Levofloxacin, Lacidofil, CJ-12420/Clarithromycin/AmoxicillinVonoprazan, Vonoprazan, Lansoprazole (Lanton), rabeprazole sodium, RHB-105, Ilaprazole + Amoxicillin, pantoprazole, Finafloxacin + Amoxicillin, Rifasutenizol capsules, and others are expected to have a significant impact on the Helicobacter Pylori Infections market in the coming years.
*
In May 2022, Biomerica, Inc. announced CE Mark for its hp+detect diagnostic test that detects Helicobacter pylori bacteria. The company will begin to market and sell its hp+detect diagnostic test in the European Union (EU) and other international countries following the registration of the product in each country in which it is sold. Source: https://www.mordorintelligence.com/industry-reports/helicobacter-pylori-diagnostics-market
*
Bio-Rad launched Platelia H. Pylori IgG, an immuno-enzymatic assay for qualitative determination of IgG antibodies, in July 2022. Serology is a non-invasive, delicate, and straightforward technique for identifying H. pylori infection. The Platelia H. Pylori IgG immunoenzymatic assay is used to determine the quality of IgG antibodies.
Helicobacter Pylori Infections Overview
Helicobacter pylori (H. pylori) is a type of bacteria that infects the stomach lining and can cause various gastrointestinal issues. It is a common infection, affecting about half of the world's population. H. pylori infections are usually acquired during childhood and can persist for many years if left untreated.
Get a Free Sample PDF Report to know more about Helicobacter Pylori Infections Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-pipeline-insight [https://www.delveinsight.com/report-store/helicobacter-pylori-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Helicobacter Pylori Infections Drugs Under Different Phases of Clinical Development Include:
*
SVT1C4610: Servatus Biopharmaceuticals
*
TNP-2198: TenNor Therapeutics (Suzhou) Limited
*
Vonoprazan: Phathom Pharmaceuticals, Inc.
*
Tegoprazan: HK inno.N Corporation
*
Esomeprazole: Elpen Pharmaceutical Co. Inc.
*
Levofloxacin: Deva Holding A.S.
*
Lacidofil: Lallemand Health Solutions
*
CJ-12420/Clarithromycin/AmoxicillinVonoprazan: HK inno.N Corporation
*
Vonoprazan: Takeda
*
Lansoprazole (Lanton): Meridian Bioscience, Inc.
*
rabeprazole sodium: Janssen Cilag Pharmaceutica S.A.C.I., Greece
*
RHB-105: RedHill Biopharma Limited
*
Ilaprazole + Amoxicillin: Il-Yang Pharm. Co., Ltd.
*
pantoprazole: Asan Medical Center
*
Finafloxacin + Amoxicillin: MerLion Pharmaceuticals GmbH
*
Rifasutenizol capsules: TenNor Therapeutics (Suzhou) Limited
Helicobacter Pylori Infections Route of Administration
Helicobacter Pylori Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Helicobacter Pylori Infections Molecule Type
Helicobacter Pylori Infections Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Helicobacter Pylori Infections Pipeline Therapeutics Assessment
*
Helicobacter Pylori Infections Assessment by Product Type
*
Helicobacter Pylori Infections By Stage and Product Type
*
Helicobacter Pylori Infections Assessment by Route of Administration
*
Helicobacter Pylori Infections By Stage and Route of Administration
*
Helicobacter Pylori Infections Assessment by Molecule Type
*
Helicobacter Pylori Infections by Stage and Molecule Type
DelveInsight's Helicobacter Pylori Infections Report covers around 5+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Helicobacter Pylori Infections product details are provided in the report. Download the Helicobacter Pylori Infections pipeline report to learn more about the emerging Helicobacter Pylori Infections therapies [https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Helicobacter Pylori Infections Therapeutics Market include:
Key companies developing therapies for Helicobacter Pylori Infections are - Takeda Pharmaceutical, AbbVie, Cumberland Pharmaceuticals, Eisai Co, Bio-Rad Laboratories, F. Hoffmann-La, Roche, Alpha Laboratories, Biohit, Biomerica, Inc., QuickNaviTM, and others.
Helicobacter Pylori Infections Pipeline Analysis:
The Helicobacter Pylori Infections pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Helicobacter Pylori Infections with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Helicobacter Pylori Infections Treatment.
*
Helicobacter Pylori Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Helicobacter Pylori Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Helicobacter Pylori Infections market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Helicobacter Pylori Infections drugs and therapies [https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of Helicobacter Pylori Infections Pipeline Drug Insight
*
Coverage: Global
*
Key Helicobacter Pylori Infections Companies: Servatus Biopharmaceuticals, TenNor Therapeutics (Suzhou) Limited, Phathom Pharmaceuticals, Inc., HK inno.N Corporation, Elpen Pharmaceutical Co. Inc., Deva Holding A.S., Lallemand Health Solutions, Takeda, Meridian Bioscience, Inc., Janssen Cilag Pharmaceutica S.A.C.I., Greece, RedHill Biopharma Limited, Il-Yang Pharm. Co., Ltd., Asan Medical Center, MerLion Pharmaceuticals GmbH, TenNor Therapeutics (Suzhou) Limited, and others
*
Key Helicobacter Pylori Infections Therapies: SVT1C4610, TNP-2198, Vonoprazan, Tegoprazan, Esomeprazole, Levofloxacin, Lacidofil, CJ-12420/Clarithromycin/AmoxicillinVonoprazan, Vonoprazan, Lansoprazole (Lanton), rabeprazole sodium, RHB-105, Ilaprazole + Amoxicillin, pantoprazole, Finafloxacin + Amoxicillin, Rifasutenizol capsules, and others
*
Helicobacter Pylori Infections Therapeutic Assessment: Helicobacter Pylori Infections current marketed and Helicobacter Pylori Infections emerging therapies
*
Helicobacter Pylori Infections Market Dynamics: Helicobacter Pylori Infections market drivers and Helicobacter Pylori Infections market barriers
Request for Sample PDF Report for Helicobacter Pylori Infections Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Helicobacter Pylori Infections Report Introduction
2. Helicobacter Pylori Infections Executive Summary
3. Helicobacter Pylori Infections Overview
4. Helicobacter Pylori Infections- Analytical Perspective In-depth Commercial Assessment
5. Helicobacter Pylori Infections Pipeline Therapeutics
6. Helicobacter Pylori Infections Late Stage Products (Phase II/III)
7. Helicobacter Pylori Infections Mid Stage Products (Phase II)
8. Helicobacter Pylori Infections Early Stage Products (Phase I)
9. Helicobacter Pylori Infections Preclinical Stage Products
10. Helicobacter Pylori Infections Therapeutics Assessment
11. Helicobacter Pylori Infections Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Helicobacter Pylori Infections Key Companies
14. Helicobacter Pylori Infections Key Products
15. Helicobacter Pylori Infections Unmet Needs
16 . Helicobacter Pylori Infections Market Drivers and Barriers
17. Helicobacter Pylori Infections Future Perspectives and Conclusion
18. Helicobacter Pylori Infections Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=helicobacter-pylori-infections-pipeline-2024-clinical-trials-assessment-fda-approvals-therapies-involved-by-delveinsight-phathom-pharma-hk-innon-corporation-elpen-pharma-deva-holding]
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Helicobacter Pylori Infections Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, Involved by DelveInsight | Phathom Pharma, HK inno.N Corporation, Elpen Pharma, Deva Holding here
News-ID: 3572643 • Views: …
More Releases from ABNewswire
Lenox Hill Hardware Store & Housewares Destination: S. Feldman Housewares Expand …
S. Feldman Housewares, the family-run Carnegie Hill favorite since 1929, has expanded its in-store selection to make it even easier for Upper East Side residents to find everyday essentials in one stop. From kitchen staples and home organization to hardware basics and those hard-to-find problem solvers, the store's Madison Avenue location continues to be a trusted resource for neighbors who appreciate knowledgeable service and genuinely helpful advice.
NEW YORK, NY -…
Insurance Industry Veteran Sounds the Alarm on Career Risk Facing New York Medic …
EAST AURORA, NY - As New York State's healthcare system continues to rely heavily on medical residents and early-career physicians, a growing financial risk is quietly emerging behind hospital doors: many of these professionals are one illness or injury away from losing their income with limited protection in place.
Kasey Labrie, a New York-based insurance agent and agency owner, is bringing attention to what she calls a "critical blind spot" in…
Chicago Family Law Attorneys Molly E. Caesar and Michael Ian Bender Announce Lau …
Chicago family law attorneys Molly E. Caesar and Michael Ian Bender have announced the launch of a newly redesigned website for Caesar & Bender, LLP [https://www.caesarbenderlaw.com/]. The new site is built to help individuals and families in the Chicago area access clear legal information and take the first step toward resolving family law matters with confidence.
Created with usability in mind, the website offers a streamlined experience for those handling sensitive…
Why More Augusta GA Area Homeowners Are Rethinking Renovation - and Choosing a P …
As homeowners across the CSRA rethink how their homes function, feel, and grow with their families, one question continues to rise to the surface: Who can I trust as my home renovation contractor? For many homeowners in the Augusta and Evans GA area, the answer has become Impact Roofing & Construction.
Rather than chasing short-term design trends or surface-level upgrades, Impact Roofing & Construction [https://impactroofingconstruction.s3.us-east-1.amazonaws.com/press/GeneralContractor-AugustaGA.html] approaches renovation with a long-term mindset-helping…
More Releases for Helicobacter
Helicobacter pylori Testing Market Is Going to Boom |• Abbott • Roche
According to Worldwide Market Reports (WMR) highlights that the "Helicobacter pylori Testing Market" is projected to experience substantial growth in the coming years. This report provides a comprehensive analysis of the market landscape using an integrated approach that includes research methodology, market size evaluation, data compilation, and insights gathered from multiple credible sources.
The study covers critical market elements such as market dynamics, drivers, restraints, challenges, threats, growth opportunities, development trends,…
Helicobacter Pylori Testing Market 2024 Size, Status and Global Outlook |
Helicobacter Pylori Testing Market Overview:
A lot of factors, such as geographic growth, segmentation, and market size by value and volume, are taken into account in the SkyQuest Technology Group research to provide a full and accurate analysis of the global Helicobacter Pylori Testing market. This outstanding research study was created specifically to provide the most latest data on significant aspects of the global Helicobacter Pylori Testing Industry. Numerous…
Helicobacter Pylori Diagnostic Market Research Report 2023 | InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Helicobacter Pylori Diagnostic Market Size, Share & Trends Analysis Report By Technology (Immunoassays, POC, Molecular Diagnostics), By End User (Hospitals, Diagnostics Laboratories, Clinics)- Market Outlook And Industry Analysis 2031"
The Global Helicobacter Pylori Diagnostic Market is estimated to reach over USD 994.69 million by 2031, exhibiting a CAGR of 6.20% during the forecast period.
Request…
Helicobacter Pylori Diagnostics Market Size - Forecast to 2026
The findings reviewed by GME stated that the Global Helicobacter Pylori Diagnostics Market would grow at a CAGR value of 7.4 percent from 2021 to 2026. With drastically increasing advancements and less complex diagnostic processes, the reliability and demand for helicobacter pylori diagnostics are increasing. Also, most developing countries have unsanitary water services and facilities, along with a lack of awareness about personal care; the helicobacter pylori bacterial infection is…
Helicobacter Pylori Testing Market: Competitive Dynamics & Global Outlook 2025
Market Research Report Store offers a latest published report on Helicobacter Pylori Testing Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Helicobacter Pylori Testing market will register a 7.5% CAGR in terms of revenue, the global market size will reach $ 781.6 million by 2025, from $ 586 million in…
Global Helicobacter Pylori Testing Market Growth 2019-2024
LP INFORMATION offers a latest published report on Helicobacter Pylori Testing Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Helicobacter Pylori Testing market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
